Differential diagnostic value of total alpha-synuclein assay in the cerebrospinal fluid between Alzheimer’s disease and dementia with Lewy bodies from the prodromal stage

Alzheimer’s Research & Therapy

Ingolf Lachmann¹  Barbara Jung²  Nathalie Philippi²  Lucie Rauch²  Anne Botzung²  Catherine Martin-Hunyadi²  Benjamin Cretin²  Catherine Demuynck²  Frédéric Blanc²  Pierre Anthony³  Thomas Lavaux⁴  Caroline Schaeffer-Agalède⁴  Olivier Bousiges⁴  Armand Perret-Liaudet⁵  Paulo Loureiro de Sousa⁶ 

[1] AJ Roboscreen GmbH;CM2R (Research and Resources Memory Centre), Geriatric Day Hospital and Neuropsychology Unit, Geriatrics Department, University Hospitals of Strasbourg;Geriatrics Department, General Hospital Centre, CM2R, Geriatric Day Hospital;Laboratory of Biochemistry and Molecular Biology, University Hospital of Strasbourg;Neurochemistry Laboratory, Biochemistry Department, Centre de Biologie et Pathologie Est, Hospices Civils de Lyon;University of Strasbourg and CNRS, ICube Laboratory UMR 7357 and FMTS (Fédération de Médecine Translationnelle de Strasbourg), Team IMIS;

关键词: Dementia with Lewy bodies;    Alzheimer’s disease;    Prodromal;    Dementia;    Cerebrospinal fluid biomarkers;    Total alpha-synuclein;   

DOI  :  10.1186/s13195-020-00684-5

来源: DOAJ

【 摘 要 】

Abstract Background Several studies have investigated the value of alpha-synuclein assay in the cerebrospinal fluid (CSF) of Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) patients in the differential diagnosis of these two pathologies. However, very few studies have focused on this assay in AD and DLB patients at the MCI stage. Methods All patients were enrolled under a hospital clinical research protocol from the tertiary Memory Clinic (CM2R) of Alsace, France, by an experienced team of clinicians. A total of 166 patients were included in this study: 21 control subjects (CS), 51 patients with DLB at the prodromal stage (pro-DLB), 16 patients with DLB at the demented stage (DLB-d), 33 AD patients at the prodromal stage (pro-AD), 32 AD patients at the demented stage (AD-d), and 13 patients with mixed pathology (AD+DLB). CSF levels of total alpha-synuclein were assessed using a commercial enzyme-linked immunosorbent assay (ELISA) for alpha-synuclein (AJ Roboscreen). Alzheimer’s biomarkers (t-Tau, P-Tau, Aβ42, and Aβ40) were also measured. Results The alpha-synuclein assays showed a significant difference between the AD and DLB groups. Total alpha-synuclein levels were significantly higher in AD patients than in DLB patients. However, the ROC curves show a moderate discriminating power between AD and DLB (AUC = 0.78) which does not improve the discriminating power of the combination of Alzheimer biomarkers (AUC = 0.95 with or without alpha-synuclein). Interestingly, the levels appeared to be altered from the prodromal stage in both AD and DLB. Conclusions The modification of total alpha-synuclein levels in the CSF of patients occurs early, from the prodromal stage. The adding of alpha-synuclein total to the combination of Alzheimer’s biomarker does not improve the differential diagnosis between AD and DLB. Trial registration ClinicalTrials.gov, NCT01876459 (AlphaLewyMa)

【 授权许可】

Unknown